AGENDIA B.V.

Agendia is world leader in gene expression analysis based diagnostics The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling Agendia was the first to commercialize a prognostic test MammaPrint that predicts the chance of breast cancer recurrence CupPrintÂ, the second product in the market of Agendia, is used for the identification of Cancers of Unknown Primary Agendia maintains close ties with NKI AVL, ensuring access to the latest developments in cancer research Apart from the development of new cancer diagnostics, Agendia offers its expertise in finding new predictive gene expression profiles to companies focusing on new drug development in the area of oncology Agendia Applying genomic profiling to enable personalized medicine